Everything below concerns quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Elongation factor 4 (EF-4) is an elongation factor that is thought to back-translocate on the ribosome during the translation of RNA to proteins. It is found near-universally in bacteria and in eukaryotic endosymbiotic organelles including the mitochondria and the plastid. Responsible for proofreading during protein synthesis, EF-4 is a recent addition to the nomenclature of bacterial elongation factors. Prior to its recognition as an elongation factor, EF-4 was known as leader peptidase A (LepA), as it is the first cistron on the operon carrying the bacterial leader peptidase. In eukaryotes it is traditionally called GUF1 (GTPase of Unknown Function 1). It has the preliminary EC number 3.6.5.n1.
These compounds are often not detected by routine toxicology tests and can be masked by the presence of a known compound in the same sample. As new compounds are discovered, known spectra are determined and entered into the databases that can be downloaded and used as reference standards. Laboratories also tend to keep in-house databases for the substances they find locally.
A fully oxygenated orthorhombic YBa2Cu3O7−x sample can be transformed into tetragonal YBa2Cu3O6 by heating in a vacuum at temperature above 973 K (700 °C). The preparation of Bi-, Tl- and Hg-based high-Tc superconductors is more difficult than the YBCO preparation. Problems in these superconductors arise because of the existence of three or more phases having a similar layered structure. Thus, syntactic intergrowth and defects such as stacking faults occur during synthesis and it becomes difficult to isolate a single superconducting phase. For Bi–Sr–Ca–Cu–O, it is relatively simple to prepare the Bi-2212 (Tc ≈ 85 K) phase, whereas it is very difficult to prepare a single phase of Bi-2223 (Tc ≈ 110 K). The Bi-2212 phase appears only after few hours of sintering at 1,130–1,140 K (860–870 °C), but the larger fraction of the Bi-2223 phase is formed after a long reaction time of more than a week at 1,140 K (870 °C). Although the substitution of Pb in the Bi–Sr–Ca–Cu–O compound has been found to promote the growth of the high-Tc phase, a long sintering time is still required.
Tazarotene, sold under the brand name Tazorac, among others, is a third-generation prescription topical retinoid. It is primarily used for the treatment of plaque psoriasis and acne. Tazarotene is also used as a therapeutic for photoaged and photodamaged skin. It is a member of the acetylenic class of retinoids. Tazarotene was approved for medical use in 1997 and is available as a generic medication.
Starting on 22 August 2009, he walked from Kennedy Airport in New York City to within 15 miles of Devil's Lake, North Dakota. This was a distance of 2,053 miles (3,304 km) and Skinner stopped his journey on 3 December 2009, after three days with windchills down to −30 Fahrenheit. During the trip Skinner had to make incisions in his feet to relieve the pressure from blisters, suffered food poisoning, met up with a wolf in Upper Michigan, had to face down two wild dogs, and had ski masks frozen to his beard in North Dakota. On the journey he appeared on television, radio and in newspaper articles. He also wrote a daily blog for the National Hospice Foundation. He met hospice patients, including one woman with a terminal illness, who said that at times she could forget she was ill, thanks to the care she received in a hospice house in Buffalo, New York. He also met a man with lung cancer who could not sleep in hospitals, where there was always someone coming to check on him. In the hospice house in Windsor, Ontario, the man had a peaceful room to himself, where he could finally get some rest.
Sources: en.wikipedia.org
Banting House features archival materials, artifacts, and other ephemera associated with Banting as co-discoverer of insulin, doctor, and artist, as well as his involvement in the first and second world wars. One gallery depicts the kind of office Banting might have had, and contains several of his belongings, including his original medicine cabinet, and a graduated cylinder Banting used during his time at the University of Western Ontario. The apothecary in the next room features a sink that Banting installed for his medical practice. Other galleries in the museum hold original belongings of Banting as well, most notably his desk and his bed frame. The bed frame is kept in Banting's bedroom, and visitors are encouraged to take a moment or a picture with it, as it is not roped off like many other areas of the museum. Additionally, an official replica of the Nobel Prize medal co-awarded to Banting and Macleod is on display, as well as many of Banting's other medals. Other displays include the military gallery, which includes a representation of the type of operating room Banting would have worked in on the field during the First World War, some information on the projects he headed during the Second World War, and an entire gallery filled with artwork done by Banting.
Knoll Pharmaceuticals was a drug development company founded by Albert Knoll and Hans Knoll in Germany in 1886. The company was taken over by German BASF in 1975, which sold it to Abbott Laboratories on 30 June 2002 for $6.9 billion. It was the developer of several drugs: Dilaudid (hydromorphone), a powerful and very water-soluble narcotic analgesic (Betäubungsmittel) introduced in 1926, as small oral tablets of a number of strengths, multipurpose (hypodermic) tablets, compounding powder, ampoules of solution for injection, and dry ampoules for reconstitution. Knoll also produced somewhat similar hydrocodone tablets named Dicodid; this drug which compares to codeine as hydromorphone compares to morphine was first synthesised and announced in Germany in 1920. The obverse sides of the oral tablets bear a stylised letter "K" and the reverse has the relevant imprint code for the medication in the locale of sale and/or number of milligrams of hydromorphone. Sibutramine, a serotonin-norepinephrine reuptake inhibitor, prescribed as an adjunct in the treatment of exogenous obesity, marketed by Abbott but withdrawn from the market in the United States and most other countries in 2010 Propafenone, an antiarrhythmic agent, marketed by Abbott. Isophan, a slightly modified version of the methamphetamine drug Pervitin, which the Nazi government in 1940 distributed to the German army and air force in an effort to win WW2.
== Background and education == Merker was born in Merseburg, the son of a general practitioner. The Russian occupation saw his father thrown in jail by the communists, and as a son of an academic, he was banned from studying at universities in the Russian occupation zone. In December 1948, at 19, he enrolled as one of the first students at the newly established Free University of Berlin, which was founded in the same month with American support in West Berlin in response to the suppression of academic freedom by the communists at the Humboldt University. He initially studied art history and archeology, as the Free University did not yet have a preclinical medical programme. He started his studies of medicine in 1950 and settled permanently in West Berlin before the construction of the Berlin Wall, after which he did not see his parents for many years. He stayed for his entire career with the Free University, which he would later describe as "an island of freedom."
Conservative leader Kemi Badenoch outlines her party's immigration policy, which reaffirms its commitment to a "strict migration cap"; she also says that her party got it "wrong" on immigration while in government. MPs will debate an online petition calling for a re-run of the 2024 general election in Westminster Hall, a secondary debating chamber, on 6 January 2025 after the petition attracted 2.8 million signatures. 28 November – Former prime minister David Cameron announces his support for an assisted dying law in the UK. Transport Secretary Louise Haigh reveals that she pleaded guilty to falsely saying a mobile phone had been stolen during a mugging before she became an MP and was given an absolute discharge by magistrates. Unite the Union announces plans to proceed with a legal challenge to overturn the UK government's cuts to Winter Fuel Payments. The Scottish Government announces that all pensioner households will receive a Winter Fuel Payment from Winter 2025–26, with those on Pension Credit receiving £200 or £300 dependent on age and the rest receiving £100. Former Conservative MP Andrea Jenkyns defects to Reform UK, and announces plans to run as Mayor of Greater Lincolnshire in May 2025. BBC News Wales reports that Senedd Conservatives will hold a vote of confidence in Welsh Conservative leader Andrew RT Davies on 3 December following a series of criticisms about his leadership. Mauritian prime minister Navin Ramgoolam asks for an independent review of the UK's deal with his country over sovereignty of the Chagos Islands.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.